The Prospect of Genomic, Transcriptomic, Epigenetic and Metabolomic Biomarkers for The Personalized Prevention of Type 2 Diabetes and Cardiovascular Diseases

被引：4

作者：

Zeljkovic, Aleksandra ^{[1
]}

Mihajlovic, Marija ^{[1
]}

Vujcic, Sanja ^{[1
]}

Guzonjic, Azra ^{[1
]}

Munjas, Jelena ^{[1
]}

Stefanovic, Aleksandra ^{[1
]}

Kotur-Stevuljevic, Jelena ^{[1
]}

Rizzo, Manfredi ^{[2
]}

Bogavac-Stanojevic, Natasa ^{[1
]}

Gagic, Jelena ^{[1
]}

Kostadinovic, Jelena ^{[3
]}

Vekic, Jelena ^{[1
,4
]}

机构：

[1] Univ Belgrade, Fac Pharm, Dept Med Biochem, Belgrade, Serbia

[2] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy

[3] Clin Hosp Ctr Bezanijska Kosa, Dept Internal Med, Belgrade, Serbia

[4] Univ Belgrade, Fac Pharm, Dept Med Biochem, Vojvode Stepe 450,POB 146, Belgrade 11000, Serbia

来源：

CURRENT VASCULAR PHARMACOLOGY | 2023年 / 21卷 / 03期

关键词：

Cardiovascular disease; diabetes; biomarker; multi-omics; prevention; personalized prevention; CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; DNA METHYLATION AGE; GENETIC RISK SCORE; ARTERY-DISEASE; STATIN THERAPY; OXIDATIVE STRESS; TELOMERE LENGTH; EXPRESSION; MICRORNA;

D O I：

10.2174/1570161121666230510141338

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cardiometabolic diseases, such as type 2 diabetes mellitus (DM) and cardiovascular disease (CVD), are a great health concern. The strategies aimed to increase awareness and prevention, in conjunction with timely diagnosis and optimal management of these conditions, represent the main lines of action to improve life expectancy and quality. In recent years, the introduction of innovative therapies for the treatment of DM and CVD has provided new hope for high-risk patients. Yet, the implementation of preventive measures in achieving cardiometabolic health is far from successful and requires further improvement. The development of cardiometabolic disorders is a complex, multifactorial process involving several metabolic pathways as well as genetic and environmental factors. Decreasing cumulative exposure during the entire life course and timely recognition and targeting of potential risk-enhancing factors could pave the way toward more successful prevention of cardiometabolic disorders. Nowadays, in the era of "omics" technologies, it is possible to identify novel biomarkers and therapeutic targets, which offers the possibility to apply an individualized approach for each patient. This review will discuss potential applications of genomic, transcriptomic, epigenetic and metabolomic biomarkers for the personalized prevention of cardiometabolic diseases.

引用

页码：185 / 196

页数：12

共 166 条

[1] Discovery of Coding Genetic Variants Influencing Diabetes-Related Serum Biomarkers and Their Impact on Risk of Type 2 Diabetes [J].

Ahluwalia, Tarunveer Singh ;

Allin, Kristine Hojgaard ;

Sandholt, Camilla Helene ;

Sparso, Thomas Hempel ;

Jorgensen, Marit Eika ;

Rowe, Michael ;

Christensen, Cramer ;

Brandslund, Ivan ;

Lauritzen, Torsten ;

Linneberg, Allan ;

Husemoen, Lise Lotte ;

Jorgensen, Torben ;

Hansen, Torben ;

Grarup, Niels ;

Pedersen, Oluf .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (04) :E664-E671

[2] Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration [J].

Angelakopoulou, Aspasia ;

Shah, Tina ;

Sofat, Reecha ;

Shah, Sonia ;

Berry, Diane J. ;

Cooper, Jackie ;

Palmen, Jutta ;

Tzoulaki, Ioanna ;

Wong, Andrew ;

Jefferis, Barbara J. ;

Maniatis, Nikolas ;

Drenos, Fotios ;

Gigante, Bruna ;

Hardy, Rebecca ;

Laxton, Ross C. ;

Leander, Karin ;

Motterle, Anna ;

Simpson, Iain A. ;

Smeeth, Liam ;

Thomson, Andy ;

Verzilli, Claudio ;

Kuh, Diana ;

Ireland, Helen ;

Deanfield, John ;

Caulfield, Mark ;

Wallace, Chris ;

Samani, Nilesh ;

Munroe, Patricia B. ;

Lathrop, Mark ;

Fowkes, F. Gerry R. ;

Marmot, Michael ;

Whincup, Peter H. ;

Whittaker, John C. ;

de Faire, Ulf ;

Kivimaki, Mika ;

Kumari, Meena ;

Hypponen, Elina ;

Power, Chris ;

Humphries, Steve E. ;

Talmud, Philippa J. ;

Price, Jackie ;

Morris, Richard W. ;

Ye, Shu ;

Casas, Juan P. ;

Hingorani, Aroon D. .

EUROPEAN HEART JOURNAL, 2012, 33 (03) :393-407

[3]

[Anonymous], 2021, LIFESTYLE MED, P2

[4] Cholesterol homeostasis is dysregulated in women with preeclampsia [J].

Antonic, Tamara D. ;

Ardalic, Daniela c ;

Vladimirov, Sandra S. ;

Banjac, Gorica S. ;

Cabunac, Petar J. ;

Zeljkovic, Aleksandra R. ;

Karadzov-Orlic, Natasa T. ;

Spasojevic-Kalimanovska, Vesna V. ;

Mikovic, Zeljko D. ;

Stefanovic, Aleksandra Z. .

POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (12)

[5]

Arnett DK, 2019, CIRCULATION, V140, pE596, DOI [10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.009, 10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.010]

[6] Cardiovascular Epigenetics Basic Concepts and Results From Animal and Human Studies [J].

Baccarelli, Andrea ;

Rienstra, Michiel ;

Benjamin, Emelia J. .

CIRCULATION-CARDIOVASCULAR GENETICS, 2010, 3 (06) :567-573

[7] Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey [J].

Banach, Maciej ;

Mazidi, Mohsen ;

Mikhailidis, Dimitri P. ;

Toth, Peter P. ;

Jozwiak, Jacek ;

Rysz, Jacek ;

Watts, Gerald F. .

EUROPEAN HEART JOURNAL, 2018, 39 (40) :3635-3640

[8] Integrating bioinformatics approaches for a comprehensive interpretation of metabolomics datasets [J].

Barupal, Dinesh Kumar ;

Fan, Sili ;

Fiehn, Oliver .

CURRENT OPINION IN BIOTECHNOLOGY, 2018, 54 :1-9

[9] MicroRNA and Microvascular Complications of Diabetes [J].

Barutta, F. ;

Bellini, S. ;

Mastrocola, R. ;

Bruno, G. ;

Gruden, G. .

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2018, 2018

[10] The Critical Role of Metabolic Pathways in Aging [J].

Barzilai, Nir ;

Huffman, Derek M. ;

Muzumdar, Radhika H. ;

Bartke, Andrzej .

DIABETES, 2012, 61 (06) :1315-1322

← 1 2 3 4 5 6 7 8 9 10 →